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ABSTRACT
A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-Saharan Africa showed RTS,
S/AS01 vaccine efficacy against malaria. We now present in-depth safety results from this study. 8922
children (enrolled at 5–17 months) and 6537 infants (enrolled at 6–12 weeks) were 1:1:1-randomized to
receive 4 doses of RTS,S/AS01 (R3R) or non-malaria control vaccine (C3C), or 3 RTS,S/AS01 doses plus
control (R3C). Aggregate safety data were reviewed by a multi-functional team. Severe malaria with
Blantyre Coma Score ≤2 (cerebral malaria [CM]) and gender-specific mortality were assessed post-hoc.
Serious adverse event (SAE) and fatal SAE incidences throughout the study were 24.2%–28.4% and
1.5%–2.5%, respectively across groups; 0.0%–0.3% of participants reported vaccination-related SAEs. The
incidence of febrile convulsions in children was higher during the first 2–3 days post-vaccination with
RTS,S/AS01 than with control vaccine, consistent with the time window of post-vaccination febrile
reactions in this study (mostly the day after vaccination). A statistically significant numerical imbalance
was observed for meningitis cases in children (R3R: 11, R3C: 10, C3C: 1) but not in infants. CM cases were
more frequent in RTS,S/AS01-vaccinated children (R3R: 19, R3C: 24, C3C: 10) but not in infants. All-cause
mortality was higher in RTS,S/AS01-vaccinated versus control girls (2.4% vs 1.3%, all ages) in our setting
with low overall mortality. The observed meningitis and CM signals are considered likely chance
findings, that – given their severity – warrant further evaluation in phase IV studies and WHO-led pilot
implementation programs to establish the RTS,S/AS01 benefit-risk profile in real-life settings.
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Introduction
The widespread implementation of malaria prevention and
control measures, such as the use of insecticide-treated nets,
improved diagnosis, and artemisinin combination therapy,
has led to considerable gains in the control of malaria.1,2
Nevertheless, malaria remains a major public health threat,
especially in young children in sub-Saharan Africa (SSA). In
2017, an estimated 219 million cases of malaria occurred
worldwide, resulting in 435,000 deaths, of which 93%
occurred in Africa. About 61% of all malaria deaths, mostly
caused by Plasmodium falciparum, were estimated to occur in
children younger than 5 years.3,4
The development and deployment of an effective malaria
vaccine is considered a further important step towards redu-
cing the disease burden. RTS,S/AS01 is a malaria vaccine
candidate targeting the circumsporozoite protein and has
proven efficacy in clinical trials.5–10 In July 2015, RTS,S/
AS01 received a positive scientific opinion from the
European Medicines Agency (EMA) under Article 58.11 In
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January 2016, the World Health Organization (WHO) recom-
mended pilot implementation of RTS,S/AS01 in children 5–-
17 months of age.12 The large phase III clinical trial conducted
in SSA in children aged 5–17 months and infants aged 6–-
12 weeks at first vaccination demonstrated vaccine efficacy
(VE) against clinical malaria of 36.3% (95% confidence inter-
val [CI] 31.8–40.5) in children and 25.9% (19.9–31.5) in
infants, over a median follow-up of 48 and 38 months from
the first vaccine dose in children and infants, respectively, in
the modified intention-to-treat population. VE against severe
malaria over the same follow-up period was 32.2% (13.7–46.9)
in children and 17.3% (−9.4–37.5) in infants.7 Efficacy, immu-
nogenicity, reactogenicity, and safety results from this trial
have been reported previously.7–10 Here, we present more
detailed safety results, both as defined per protocol and from
post-hoc analyses. We further investigated the increased risk
of febrile convulsions and the safety signals related to menin-
gitis and cerebral malaria that were previously identified in
this trial.7–10,12,13 In addition, analyses on gender-specific
mortality and in specific subpopulations such as preterm
infants and infants and children with low weight-for-age are
described in detail.
Results
Study participants and reactogenicity
In total, 8922 children (enrolled at 5–17months) and 6537 infants
(enrolled at 6–12 weeks) were randomized to 1 of 3 regimens: 4
doses of RTS,S/AS01 (R3R group), 3 doses of RTS,S/AS01 fol-
lowed by 1 dose of control vaccine (R3C group), or 4 doses of
control vaccine (C3C group), administered at study months (M)
0, 1, 2, and 20. 8447 (95%) children and 6234 (95%) infants
received the first 3 doses and 7384 (83%) children and 5488
(84%) infants received a fourth vaccine dose 18 months post-
dose 3. 6187 (69%) children and 4637 (71%) infants completed
the entire study.7 Children were followed up for a median of
48 months (interquartile range 39–50 months) and infants for
38 months (34–41 months) after the first vaccine dose. Baseline
characteristics were similar in the 3 study groups.7 The mean age
at dose 1 was 10.6–10.7 months across groups in the children
cohort and 7.1–7.2 weeks in the infant cohort. Reactogenicity after
the first 3 doses8,9 and post-dose 47 has been previously reported
(Supplementary tables S1 and S2). On further investigation of
the timing of the febrile reactions post-vaccination, we found that
the increased incidence of fever (axillary temperature ≥37.5°C)
following RTS,S/AS01 vaccination mainly occurred on the day
after vaccination and fever mostly resolved within 1 day
(Supplementary figure S1).
Serious adverse events
The serious adverse event (SAE) incidences over the entire
study period in the R3R, R3C, and C3C groups were 24.2%,
25.3%, and 28.4%, respectively, in children and 26.6%, 27.6%,
and 28.4% in infants (Table 1). Across all groups and in chil-
dren and infants, respectively, the most frequently reported
SAEs were malaria (9.9%–14.2%; 8.3%–10.7%), pneumonia
(6.8%–7.5%; 9.3%–10.0%), febrile convulsions (5.3%–6.2%;
4.1%–4.6%), gastroenteritis (5.0%–6.0%; 7.4%–7.9%), and ane-
mia (4.2%–6.6%; 4.1%–5.3%).7 The incidence of SAEs that were
judged by investigators to be causally related to vaccination
ranged between 0.0% and 0.3% in both age categories, and most
of them were fever-related.
The study population also included HIV-infected children
and infants, although no systematic screening for HIV infection
was performed. The proportion of participants identified and
confirmed as HIV-infected between screening and study end
(SE) was balanced across treatment groups: 0.9% in the control
group and 1.0% in the RTS,S/AS01 groups for the combined age
categories. Among HIV-infected children and infants, the safety
profile appeared to be similar between RTS,S/AS01 and the
control vaccine recipients. Detailed results for this subpopula-
tion will be reported elsewhere (manuscript in preparation).
Fatal SAEs
No imbalance in fatal SAE incidence was observed between
the treatment groups over the 30-day post-vaccination period
and over the entire study period (CIs on group estimates
overlapped) (Table 1). A total of 326 fatal SAEs were reported
for children (R3R: 127 in 61 children; R3C: 94 in 51 children;
C3C: 105 in 46 children) and 269 for infants (R3R: 85 in 51
infants; R3C: 104 in 55 infants; C3C: 80 in 42 infants). No
fatality was considered by the investigators as related to vac-
cination. The most frequently reported fatal SAEs over the
entire study period were
malaria (0.3%–0.4%), pneumonia (0.2%–0.5%), gastroenteritis
(0.2%–0.5%), anemia (0.2%–0.4%), and convulsions (0.3%) in
the
5–17 months age group, and pneumonia (0.4%–0.7%), gastro-
enteritis (0.5%–0.6%), anemia (0.1%–0.6%), malaria (0.2%–
0.4%), and sepsis (0.2%–0.3%) in the 6–12 weeks age group.
Safety in children and infants with low weight-for-age
The incidence of SAEs reported prior to dose 4 (M0–M20)
and following the fourth dose (M21–SE) in children and
infants with a low or very low weight-for-age at baseline
(low: z-score ≤-2 but >-3; very low: z-score ≤-3) were in the
same range in the RTS,S/AS01 and control groups (Table 1).
Safety in preterm infants
Safety up to M20 was evaluated in 362 infants who were born
prematurely. The majority (approximately 90% in both
groups) had a gestational age of 33–36 weeks; the 7 infants
born with a gestational age below 30 weeks were all in the
RTS,S/AS01 group (Supplementary table S3). SAE incidences
in preterm infants were 19.7% in the RTS,S/AS01 and 11.0%
in the control group (overlapping CIs) (Table 1).
Fatal SAEs were reported in 8 (3.3%; 95% CI: 1.4–6.4)
preterm infants receiving RTS,S/AS01 (Fallot’s tetralogy,
HIV infection, bronchopneumonia, pneumonia, and pneumo-
coccal meningitis and sepsis) and 1 (0.8%; 0.0–4.6) preterm
infant receiving control vaccine (HIV infection and tubercu-
losis). One fatal SAE occurred in an infant born at
a gestational age <30 weeks. None of the fatal SAEs were
considered related to vaccination.
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Adverse events of special interest
Febrile convulsions
During the 7-day post-vaccination period, a trend for
a higher incidence of generalized convulsive seizures (level
1–3 of Brighton Collaboration Working Group [BCWG]
diagnostic certainty) in RTS,S/AS01 vaccinees compared to
controls was observed after the first 3 doses in children,
and after the fourth dose in both children and infants
(Table 2).7,10 The incidence of febrile convulsions within
7 days post-vaccination rose with increasing dose numbers,
up to 2.5 per 1,000 doses in children and 2.2 per 1,000
doses in infants following the fourth dose in the R3R
group. The distribution of time-to-onset of these cases
indicated that febrile convulsions mainly happened within
the first 2–3 days after dose 3 and 4 in children
(Supplementary Figure S2).
This trend was confirmed in a post-hoc self-controlled
case-series analysis of febrile convulsions in children who
received any RTS,S/AS01 dose. This analysis showed an
increased risk during the two assessed risk periods (within 3
and 7 days post-vaccination) compared with the respective
control periods. The highest risk ratio was observed for the
3-day period (Table 2). This is consistent with the time
window of febrile reactions following RTS,S/AS01.
However, the overall rate of febrile convulsions reported as
SAE in childrenwas not increased in the RTS,S/AS01 compared to
the control group within 30 days post-vaccination (1.0% vs 0.8%
following the first 3 doses; R3R: 1.1%, R3C: 0.9%, C3C: 1.1%
following dose 4) or from M0–SE (R3R: 5.3%, R3C: 6.2%,
C3C: 5.5%).
Rashes and mucocutaneous lesions
The incidence of rashes and mucocutaneous lesions occurring
within 30 days post-vaccination in infants was balanced across
groups (29.8% for the pooled RTS,S/AS01 group and 29.4%
for the control group after the first 3 doses).
Potential immune-mediated disorders
During the entire study, 16 SAEs with Medical Dictionary for
Regulatory Activities (MedDRA; version 18) terms included in
the predefined list provided in the protocol (Supplementary
table S4) were reported as potential immune-mediated disor-
der (pIMDs) (R3R: 8, R3C: 2, C3C: 6). None were considered
causally related to vaccination. Review of the cases did not
show any safety signals because no trends in time-to-onset
after vaccination or type of pIMD were observed.
Meningitis
Following the primary analysis of the current study, an imbalance
in the number of meningitis cases with any etiology was observed
Table 1. Serious adverse events.
R3R R3C C3C
N % (95% CI) N % (95% CI) N % (95% CI)
At least one SAE (M0–SE)
5–17M (children) 2976 24.2% (22.7–25.8) 2972 25.3% (23.7–26.9) 2974 28.4% (26.8–30.1)
6–12W (infants) 2180 26.6% (24.8–28.5) 2178 27.6% (25.8–29.6) 2179 28.4% (26.5–30.4)
At least one SAE (M0–SE), excluding malaria
5–17M (children) 2976 22.6% (21.1–24.2) 2972 23.7% (22.2–25.3) 2974 26.4% (24.8–28.0)
6–12W (infants) 2180 25.8% (24.0–27.7) 2178 26.7% (24.9–28.6) 2179 27.1% (25.3–29.0)
At least one SAE within 30 days post–vaccination
5–17M (children) 2976 6.1% (5.3–7.0) 2972 6.0% (5.1–6.9) 2974 6.7% (5.8–7.6)
6–12W (infants) 2180 4.8% (4.0–5.8) 2178 5.6% (4.7–6.7) 2179 5.2% (4.3–6.2)
At least one SAE before dose 4 (M0–M20) RTS,S/AS01 Control
5–17M, all children 5949 18.6% (17.6–19.6) 2974 22.7% (21.2–24.3)
5–17M, low weight-for-age 695 25.0% (21.9–28.4) 364 24.5% (20.1–29.2)
5–17M, very low weight-for-age 207 26.6% (20.7–33.1) 97 28.9% (20.1–39.0)
6–12W, all infants 4358 22.0% (20.8–23.3) 2179 23.1% (21.3–24.9)
6–12W, low weight-for-age 221 28.5% (22.7–34.9) 126 30.2% (22.3–39.0)
6–12W, very low weight-for-age 147 32.7% (25.2–40.9) 67 25.4% (15.5–37.5)
6–12W, preterm 244 19.7% (14.9–25.2) 118 11.0% (6.0–18.1)
At least one SAE post-dose 4 (M21–SE) R3R R3C C3C
5–17M, all children 2681 10.3% (9.2–11.5) 2719 11.6% (10.4–12.9) 2702 10.6% (9.5–11.8)
5–17M, low weight-for-age 277 11.6% (8.0–15.9) 304 13.2% (9.6–17.5) 297 12.8% (9.2–17.1)
5–17M, very low weight-for-age 48 10.4% (3.5–22.7) 50 16.0% (7.2–29.1) 60 18.3% (9.5–30.4)
6–12W, all infants 1966 9.2% (7.9–10.5) 1996 9.7% (8.4–11.1) 1976 10.2% (8.9–11.6)
6–12W, low weight-for-age 232 14.7% (10.4–19.9) 211 10.0% (6.3–14.8) 195 12.3% (8.0–17.8)
6–12W, very low weight-for-age 48 12.5% (4.7–25.2) 47 19.1% (9.1–33.3) 68 22.1% (12.9–33.8)
At least one fatal SAE (M0–SE) R3R R3C C3C
5–17M, all children 2976 2.0% (1.6–2.6) 2972 1.7% (1.3–2.3) 2974 1.5% (1.1–2.1)
5–17M, girls 1467 2.4% (1.7–3.3) 1500 2.1% (1.5–3.0) 1503 1.1% (0.7–1.8)
5–17M, boys 1509 1.7% (1.1–2.5) 1472 1.3% (0.8–2.0) 1471 2.0% (1.3–2.8)
6–12W, all infants 2180 2.3% (1.7–3.1) 2178 2.5% (1.9–3.3) 2179 1.9% (1.4–2.6)
6–12W, girls 1064 2.5% (1.7–3.7) 1060 2.7% (1.8–3.9) 1100 1.5% (0.8–2.4)
6–12W, boys 1116 2.2% (1.4–3.2) 1118 2.3% (1.5–3.4) 1079 2.4% (1.6–3.5)
At least one fatal SAE within 30 days
post-vaccination
R3R R3C C3C
5–17M (children) 2976 0.3% (0.1–0.6) 2972 0.2% (0.1–0.4) 2974 0.2% (0.1–0.4)
6–12W (infants) 2180 0.6% (0.3–1.0) 2178 0.5% (0.3–0.9) 2179 0.3% (0.1–0.6)
R3R, group receiving 4 doses of RTS,S/AS01; R3C, group receiving 3 doses of RTS,S/AS01 plus 1 dose of control vaccine; C3C, group receiving 4 doses of control
vaccine; N, total number of children/infants in the group; %, percentage of children/infants with at least one SAE; M, months; W, weeks; SE, study end; CI,
confidence interval; SAE, serious adverse event. Low weight-for-age defined as z-score ≤-2 but >-3, very low weight-for-age as z-score ≤-3.
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over the first year of follow-up post-dose 3.9,10 The analysis at SE
showed that this imbalance in meningitis cases, which was con-
sidered a safety signal,14 persisted in the 5–17 months age group
only.7 From M0–SE, 40 meningitis cases of any etiology were
reported: 22 cases in children (R3R: 11, R3C: 10, C3C: 1) and 18
cases in infants (R3R: 5, R3C: 7, C3C: 6). The relative risk in
children over the entire study period was statistically significant:
11.0 for R3R vs C3C and 10.0 for R3C vs C3C (Table 3). When
assessed over follow-up periods from dose 1 up to 12 months or
18 months post-dose 3, the relative risk (R3R+R3C vs C3C) in
children was 5.5 and 8.0, respectively.8,10 Following the fourth
RTS,S/AS01 dose only 1 case in children and no cases in infants
were reported. Across all treatment groups and both age cate-
gories, 58% of cases (23/40) occurred within 12 months after the
first 3 doses; 55% of the cases in children (12/22; R3R: 6, R3C: 5,
C3C: 1) and 61% of the cases in infants (11/18; R3R: 5, R3C: 4,
C3C: 2). However, no cluster in time-to-onset was observed and
cases occurred sporadically throughout the study (Figure 1) and
over the entire age range of the participants (Supplementary
figure S3). Of all meningitis cases, 38% (15/40) were reported in
Lilongwe, Malawi, but no clustering in time or etiology indicated
an outbreak in this region (Figure 2 and Supplementary figure
S4). Pathogens were identified in 53% (21/40) of meningitis cases:
20 cases with bacterial pathogens and 1 viral meningitis case
(Table 3).
To further analyze the safety signal for meningitis, a larger
number of SAEs (n = 55) including all central nervous system
(CNS) infection/inflammation terms were reviewed by two inde-
pendent external experts. Among these 55 CNS infection/
inflammation cases (including the 40 meningitis cases reported
by the investigators), 23 were confirmed as meningitis (Table 3),
all of which were previously diagnosed as meningitis by the
investigators. Of the 17 meningitis cases reported by the inves-
tigators that were not confirmed by the experts, 10 had occurred
in children and 7 in infants. The imbalance between groups in
the 5–17 months age category remained among meningitis cases
confirmed by external experts.
Cerebral malaria
To further investigate the previously observed increased risk
of severe malaria between M21 and SE in children in the R3C
group compared to the C3C and R3R groups,7 we retrospec-
tively looked in more detail into hospitalized severe malaria
cases. This analysis revealed a safety signal for cerebral
malaria (CM).12,13 For this analysis, we used a computer
algorithm to identify cases with parasitemia >5,000/µL and
a Blantyre coma score (BCS) ≤2 as a proxy for cerebral
malaria (CM), regardless of whether the CM clinical diagnosis
was confirmed by the investigators and without excluding
children with comorbidities. Among the 53 cases identified
as CM by this algorithm in the 5–17 months age group (M0–
SE), statistically significantly more CM cases were identified
in children vaccinated with RTS,S/AS01 compared to control
(R3R: 19, R3C: 24, C3C: 10; p value: 0.0276 using Fisher exact
test) (Table 4). This was not observed in infants (R3R: 6, R3C:
7, C3C: 7). No well-defined clustering in time-to-onset after
vaccination was observed (Figure 3). Of note, an imbalance
in CM cases was also observed before dose 4 (M0–M20) when
comparing the R3R group (7 cases) and R3C group (15 cases)
even though these children received the same vaccines up to
that point (Table 4).
To gain understanding of the CM signal, 340 hospitalized
severe malaria cases with parasitemia >0/µL and with at least one
neurological marker of severe disease (BCS ≤2, or seizure, or
prostration) were reviewed retrospectively by two independent
external experts. Among these cases, there were 37 for which at
least one expert could not rule out a diagnosis of CM and which
were considered as possible CM cases. Of these 37 cases, 23 were
classified as “confirmed CM” by at least one expert. For 18 of
these, both experts agreed it was CM (Table 4). 45% (24/53) of
the CM cases identified by the computer algorithm were con-
sidered as “not CM” by the experts, and 8 new cases considered
as possible CM by the experts had not been identified as CM by
the algorithm. The same pattern, in terms of study period (M0–
M20 or M21–SE) and treatment group distribution, was
Table 2. Febrile convulsions incidence and self-controlled case-series analysis.
Incidence per 1,000 vaccine doses of febrile convulsions with diagnostic certainty level 1–3 (Brighton collaboration), within 7 days after each dose
5–17months age category (children) 6–12 weeks age category (infants)
N n Incidence (95% CI) N n Incidence (95% CI)
First 3 doses
RTS,S/AS01 17,306 18 1.0 (0.6–1.6) 12,739 2 0.2 (0.0–0.6)
Control 8728 5 0.6 (0.2–1.3) 6403 3 0.5 (0.1–1.4)
Dose 4
R3R 2447 6 2.5 (0.9–5.3) 1825 4 2.2 (0.6–5.6)
R3C 2472 3 1.2 (0.3–3.5) 1837 0 0.0 (0.0–2.0)
C3C 2473 1 0.4 (0.0–2.3) 1827 1 0.5 (0.0–3.0)
SCCS Risk Ratio (95% CI) of febrile convulsions after each of the first 3 doses (5–17 months age category)
Risk period R3R R3C R3R+R3C C3C
3 days (days 0–2) 3.8 (1.7–8.7) 2.3 (0.8–6.0) 3.0 (1.6–5.6) 0.8 (0.2–3.5)
7 days (days 0–6) 1.9 (0.9–4.2) 2.2 (1.0–4.9) 2.1 (1.2–3.6) 1.1 (0.4–2.8)
SCCS Risk Ratio (95% CI) of febrile convulsions post-dose 4 (5–17 months age category)
Risk period R3R R3C C3C
3 days (days 0–2) 6.0 (2.1–16.9) 4.5 (0.4–49.6) 0.0
7 days (days 0–6) 2.9 (1.0–7.9) 6.6 (0.6–72.5) 0.4 (0.1–2.9)
R3R, group receiving 4 doses of RTS,S/AS01; R3C, group receiving 3 doses of RTS,S/AS01 plus 1 dose of control vaccine; C3C, group receiving 4 doses of control
vaccine; N, total number of vaccine doses administered in the group; n, number of vaccine doses followed by febrile convulsions; CI, confidence interval. Risk ratio
is the risk ratio of the self-controlled case-series (SCCS) analysis, comparing the incidence in a given risk period (3 and 7 days post-vaccination) to the incidence in
the corresponding control period (day 4–30 and day 8–30 post-vaccination, respectively).
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observed for the cases identified by the experts as for the ones
previously identified by the computer algorithm.
Gender-specific mortality
As previously reported,15 all-cause mortality in girls (all ages,
M0–SE) who received RTS,S/AS01 (123/5091 [2.4%; 2.0–2.9])
was higher than in girls who received control vaccine (33/
2603 [1.3%; 0.9–1.8]), a difference not observed in boys
(95/5215 [1.8%; 1.5–2.2] vs 55/2550 [2.2%; 1.6–2.8]). Since
long-term outcomes such as death are multifactorial and
prone to confounding, mortality in the trial population was
evaluated post-hoc by modeling known risks factors by Cox
regression. Explanatory variables included in the model were
RTS,S/AS01 vaccination, gender, age category, trial site, HIV
status (which was not systematically collected in all partici-
pants), baseline anemia, distance from inpatient facility, and
low weight-for-age at baseline. As the effect of RTS,S/AS01
vaccination on mortality was observed to be modified by
gender (p value: 0.0014), we performed subgroup analyses
by gender. In girls, mortality was different across trial sites
and increased mortality was associated with HIV positivity,
low weight-for-age, baseline anemia, RTS,S/AS01 vaccination
(3 or 4 doses vs control), and the younger age cohort
(6–12 weeks vs 5–17 months) (Supplementary table S5).
Except for RTS,S/AS01 vaccination and baseline anemia, the
same risk factors were observed for boys (Supplementary
table S5). No clustering in time to death after vaccination
was observed (not shown). We found no obvious pattern in
the cause of death that could explain the gender-specific
imbalance in mortality (Supplementary table S6).
Discussion
We have previously reported that a 4-dose regimen of RTS,S/
AS01 was efficacious and provided the strongest benefit in
terms of impact against clinical and severe malaria in children
aged 5–17 months at the time of the first vaccination.16
Additionally, reductions in overall hospital admissions,
admissions because of malaria, severe anemia, and the need
Table 3. Meningitis cases.
Meningitis cases based on clinical diagnosis by treating physician, n
5–17 months age category (children) 6–12 weeks age category (infants)
Before dose 4 (M0–M20)
R3R R3C C3C R3R R3C C3C
N = 2976 N = 2972 N = 2974 N = 2180 N = 2178 N = 2179
Meningitis (no pathogen identified) 4 5 1 2 2 2
Meningitis haemophilus 1 0 0 0 0 0
Meningitis meningococcal 3 1 0 0 0 0
Meningitis pneumococcal 0 1 0 1 2 1
Meningitis tuberculous 0 0 0 0 0 0
Meningitis viral 1 0 0 0 0 0
Meningitis salmonella 0 0 0 2 1 0
Meningitis total 9 7 1 5 5 3
Post-dose 4 (M21–SE)
R3R R3C C3C R3R R3C C3C
N = 2681 N = 2719 N = 2702 N = 1996 N = 1996 N = 1976
Meningitis (no pathogen identified) 1a 0 0 0 1 1
Meningitis haemophilus 0 2 0 0 1 1
Meningitis meningococcal 0 1 0 0 0 0
Meningitis pneumococcal 0 0 0 0 0 1
Meningitis tuberculous 1 0 0 0 0 0
Meningitis viral 0 0 0 0 0 0
Meningitis salmonella 0 0 0 0 0 0
Meningitis total 2 3 0 0 2 3
Relative risk for meningitis
5–17 months age category (children) 6–12 weeks age category (infants)
Before dose 4 (M0–M20) R3R+R3C vs C3C: R3R+R3C vs C3C:
8.0 (95% CI: 1.1–60.3)b 1.5 (95% CI: 0.4–5.6)b
Entire study (M0–SE) R3R vs C3C: 11.0 (95% CI: 1.4–85.1) R3R vs C3C: 0.8 (95% CI: 0.3–2.7)
R3C vs C3C: 10.0 (95% CI: 1.3–78.1) R3C vs C3C: 1.2 (95% CI: 0.4–3.5)
Meningitis and other central nervous system infections assessed by external experts, n
5–17 months age category (children) 6–12 weeks age category (infants)
Before dose 4 (M0–M20)
R3R R3C C3C R3R R3C C3C
Confirmed meningitis 5 4 0 3 4 1
No meningitis 3 2 2 3 2 3
Undetermined 4 2 3 2 0 0
Post-dose 4 (M21–SE)
R3R R3C C3C R3R R3C C3C
Confirmed meningitis 1 2 0 0 1 2
No meningitis 1 2 0 0 0 1
Undetermined 1 0 0 0 1 0
R3R, group receiving 4 doses of RTS,S/AS01; R3C, group receiving 3 doses of RTS,S/AS01 plus 1 dose of control vaccine; C3C, group receiving 4 doses of control
vaccine; N, total number of children/infants per group; n, number of cases within the specified category; CI, confidence interval; M, month; SE, study end.
a This case occurred more than 20 months after dose 1, however, dose 4 was not given.
b RTS,S Clinical Trials Partnership PLoS Med 2014; 11: e1001685.
Confirmed meningitis, if the clinical pictures and the lab results were consistent with diagnosis of meningitis; undetermined, if the clinical pictures and/or the lab
results were not consistent with diagnosis of meningitis and not consistent with another diagnosis, or were missing; no meningitis, if the clinical pictures and the
lab results were consistent with another diagnosis.
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for blood transfusion in children were observed. We also
previously reported an increased risk of febrile convulsions
in children vaccinated with RTS,S/AS01 in our large double-
blind, randomized, phase III trial in SSA.7,10 In addition, two
safety signals were identified in this trial: an increased number
of meningitis and cerebral malaria cases in RTS,S/AS01-
vaccinated children compared to controls.7–10,12,13 In this
manuscript, we reported more detailed results on these safety
Figure 1. Meningitis cases by time-to-onset after dose 1 and by treatment group.
R3R, group receiving 4 doses of RTS,S/AS01; R3C, group receiving 3 doses of RTS,S/AS01 plus 1 dose of control vaccine; C3C, group receiving 4 doses of control
vaccine.
Figure 2. Distribution of meningitis cases by site and etiology in both age categories.
R3R, group receiving 4 doses of RTS,S/AS01; R3C, group receiving 3 doses of RTS,S/AS01 plus 1 dose of control vaccine; C3C, group receiving 4 doses of control
vaccine.
One case with viral etiology is included in the “No pathogen identified” category (R3R group).
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signals and described safety outcomes in specific subpopula-
tions in the trial.
There was no imbalance between the groups in terms of
percentages of children and infants with adverse events (AEs)
and SAEs, except those that are discussed below. Of note, no
difference was observed for sepsis or pneumonia cases, which
were assessed as secondary objectives of this study.7
Febrile convulsions form a particular subgroup of generalized
convulsive seizures that occur in 5% of children and can occur
with different infectious diseases including malaria.17 Febrile
convulsions are the most common seizures occurring after vacci-
nation. An increased incidence of febrile convulsions was
observed during the first 2–3 days after RTS,S/AS01 vaccination
in children 5 months or older. The higher risk for febrile convul-
sions following dose 3 and 4 is in line with the expected age
distribution of febrile convulsions: children aged 3 months to
6 years,18 with a peak at 18 months.19 The increased risk of febrile
convulsions during the first 2–3 days after RTS,S/AS01 vaccina-
tion is consistent with the risk period for post-vaccination febrile
reactions observed in this study (mostly on the day after
Table 4. Distribution of severe malaria manifestations.
Hospitalized severe malaria* classified by specific markers of severe disease, n (%)
5–17 months age category (children) 6–12 weeks age category (infants)
Before dose 4 (M0–M20)
R3R R3C C3C R3R R3C C3C
N = 86 N = 119 N = 158 N = 82 N = 66 N = 86
BCS ≤2 (compatible with CM) 7 (8.1) 15 (12.6) 6 (3.8) 2 (2.4) 3 (4.5) 4 (4.7)
Hb ≥5 g/dL 6 (7.0) 10 (8.4) 5 (3.2) 0 (0.0) 2 (3.0) 3 (3.5)
Hb <5 g/dL 1 (1.2) 5 (4.2) 1 (0.6) 2 (2.4) 1 (1.5) 1 (1.2)
Hb <5 g/dL (and BCS >2) 11 (12.8) 14 (11.8) 29 (18.4) 13 (15.9) 17 (25.8) 17 (19.8)
Other 67 (77.9) 90 (75.6) 123 (77.9) 65 (79.3) 46 (69.7) 65 (75.6)
Missing 1 (1.2) 0 (0.0) 0 (0.0) 2 (2.4) 0 (0.0) 0 (0.0)
Post-dose 4 (M21–SE)
R3R R3C C3C R3R R3C C3C
N = 76 N = 103 N = 76 N = 53 N = 63 N = 68
BCS ≤2 (compatible with CM) 12 (15.8) 9 (8.7) 4 (5.3) 4 (7.6) 4 (6.4) 3 (4.5)
Hb ≥5 g/dL 11 (14.5) 9 (8.7) 2 (2.6) 4 (7.6) 4 (6.4) 2 (3.0)
Hb <5 g/dL 1 (1.3) 0 (0.0) 2 (2.6) 0 (0.0) 0 (0.0) 1 (1.5)
Hb <5 g/dL (and BCS >2) 11 (14.5) 18 (17.5) 17 (22.4) 15 (28.3) 15 (23.8) 19 (27.9)
Other 53 (69.7) 75 (72.8) 54 (71.1) 34 (64.2) 42 (66.7) 45 (66.2)
Missing 0 (0.0) 1 (1.0) 1 (1.3) 0 (0.0) 2 (3.2) 1 (1.5)
Cerebral malaria following external expert adjudication (5–17 months age category), n
Before dose 4 (M0–M20) Post-dose 4 (M21–SE)
R3R R3C C3C R3R R3C C3C
N’ = 52 N’ = 69 N’ = 75 N’ = 40 N’ = 60 N’ = 44
Possible CM 3 10 7 7 8 2
Confirmed (by both experts) 2 4 3 2 6 1
Confirmed (by 1 expert) 0 2 1 1 0 1
Uncertain (by 1 or both experts) 1 4 3 4 2 0
No CM 49 59 68 33 52 42
R3R, group receiving 4 doses of RTS,S/AS01; R3C, group receiving 3 doses of RTS,S/AS01 plus 1 dose of control vaccine; C3C, group receiving 4 doses of control vaccine; N,
number of children/infants hospitalized with severe malaria, *secondary case definition 1 (>5,000 parasites/µL and at least onemarker of severe disease, without exclusion
of comorbidities); N’, number of children hospitalized with severe malaria with >0 parasites/µL and at least one neurological marker of severe disease, i.e., BCS ≤2,
prostration or 2 or more seizures; n (%), number (percentage) of cases within the specified category; M, month; SE, study end; CM, cerebral malaria; BCS, Blantyre coma
score; Hb, hemoglobin; other, BCS >2 and Hb ≥5.0 g/dL and at least one of the following: prostration, respiratory distress, 2 or more seizures, hypoglycemia <2.2 mmol/L,
acidosis base excess ≤-10.0 mmol/L, or lactate ≥5.0 mmol/L; missing, Hb or BCS unavailable so syndrome classification could not be determined; possible CM, at least one
expert could not exclude a diagnosis of CM, i.e., classified the case as “Confirmed CM” or as “Uncertain CM”; no CM, both experts classified the case as “Not CM”; uncertain,
both experts classified the case as “Uncertain CM” or one expert classified the case as “Uncertain and one as “Not CM”.
Figure 3. Cerebral malaria cases (identified per computer algorithm) by time-to-onset after dose 1 and by treatment group (5–17 months age category).
R3R, group receiving 4 doses of RTS,S/AS01; R3C, group receiving 3 doses of RTS,S/AS01 plus 1 dose of control vaccine; C3C, group receiving 4 doses of control
vaccine.
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vaccination) and confirms that convulsions occurring soon after
RTS,S/AS01 administration were mostly triggered by vaccination-
induced fever, as observed with other pediatric vaccines.18,20–25
No imbalance was observed over the 30-day post-vaccination
period or from M0–SE, possibly because of the reduction of
malaria episodes and associated malaria-related febrile seizures
in the RTS,S/AS01-vaccinated children.
An imbalance in the number of meningitis cases was pre-
viously noted in this trial, with meningitis being more frequently
reported among children in the RTS,S/AS01 groups compared to
control children before the fourth dose.8,10 While this imbalance
persisted in children over the entire follow-up,7 it was not
observed when comparing the R3R with the R3C group after the
fourth vaccine dose. The etiology of meningitis cases was hetero-
geneous, including different pathogens common in this popula-
tion. No cluster in time-to-onset after vaccination that might
suggest a temporal relationship between vaccination and the
occurrence of meningitis nor a temporal clustering of cases that
might suggest an outbreak of epidemic meningitis was observed
throughout the whole follow-up. Furthermore, 38% of cases were
reported in one study site (Lilongwe, Malawi), but were not
associated with any recognized meningitis outbreak in Malawi
during the study period. Differences in the number of meningitis
cases reported by the investigators (n = 40) compared to those
confirmed by the external experts (n = 23) are related to the more
stringent case definition requiring consensus of both experts, and
the fact that investigators also reported suspected meningitis cases
without laboratory confirmation. An imbalance of meningitis has
not been observed in other RTS,S/AS01 trials.26 The available pre-
clinical toxicology and bio-distribution data from animal studies
on RTS,S and AS01 did not reveal any treatment-related clinical
or histological signs of meningitis, encephalitis, convulsion, neu-
rotoxicity, or inflammation of the brain in any of the examined
animals.27,28 It is currently unknown if a causal link between the
vaccine and meningitis is biologically plausible. The most likely
hypothesis to explain the meningitis signal seems to be a chance
finding, due to the single case ofmeningitis in the control group of
approximately 3000 children followed for almost 4 years. While
there are no robust estimates of background incidence rates of
meningitis in SSA, it is striking to see that, in infants, 6 meningitis
cases were observed among the control group of approximately
2000 infants followed for 3 years, of which 4 occurred at an age of
10months or older (Supplementary figure S3). The hypothesis of
a probable chance finding was also pointed out by investigators,
the independent data monitoring committee, consulted external
experts, WHO, and EMA.12,29 The meningitis signal will never-
theless be closely monitored during phase IV studies and the pilot
implementations. Details on the phase IV studies can be found on
gsk-studyregister.com (study identifiers: 115055, 115056, 116682)
and ClinicalTrials.gov (NCT02374450, NCT02251704).
Cerebral malaria cases were not clinically confirmed by the
investigators; they were identified by a highly sensitive, but
possibly poorly specific computer algorithm based on the coma
score. Severe malaria cases with any neurological marker of
severe disease were therefore reviewed by two external experts,
who identified fewer possible CM cases (n = 37, including some
new cases) compared to the computer algorithm (n = 53).
Nevertheless, the distribution across the groups was similar to
that identified with the algorithm, with more CM cases noted in
children (5–17 months age category) who received any dose of
RTS,S/AS01 compared to the control group. The time-to-onset
of the CM cases did not show a well-defined clustering that
might indicate a direct effect of the vaccine or an indirect effect
related to rebound. Currently we have identified no biologically
plausible explanation for how a pre-erythrocytic vaccine could
directly affect the pathogenesis of severe disease occurring after
the blood-stage infection. Theoretically, an increase in CM could
be a result of delayed exposure to malaria and delayed acquired
immunity in the setting of ongoing malaria transmission. Any
malaria intervention has the potential to result in such a rebound
effect, especially in areas of high transmission. However, avail-
able evidence on a possible rebound effect due to RTS,S/AS01
vaccination is inconclusive.30–33
Another hypothetical explanation for the observed imbal-
ance in meningitis and CM cases may be that the low number
of cases in the control group in the 5–17 months age category
may be due to a non-specific protective effect on CNS infec-
tions of the rabies control vaccine these children received.34
Further studies would be needed to investigate the hypothesis
of non-specific vaccine effects.
The safety profile in preterm infants and children with low
weight-for-age was similar to that in the global study popula-
tion. There was a trend for a higher proportion of preterm
infants with SAEs and fatal SAEs. However, none of these
SAEs was deemed related to vaccination and the study was
not designed to specifically assess safety in preterm infants.
There was no indication of an increased risk in children with
malnutrition and therefore, no indication that these children
should be excluded from future immunization programs.
Despite the significant reductions in severe malaria, severe
malarial anemia, and blood transfusions, which serve as proximal
markers of mortality reduction, no significant effect of RTS,S/
AS01 vaccination on all-cause mortality was noted in our trial.7
This may be due to the close follow-up, access to quality care, and
prompt treatment of all participants enrolled in this phase III
study when necessary, but could also be due to the limited
power to detect an effect on overall mortality. Malaria is
a treatable disease and mortality from severe malaria can largely
be avoided with prompt antimalarial treatment and, when
required, blood transfusion.35–38 In a case-control study in one
of our study sites, children participating in this trial had a 70%
lower mortality, regardless of the study group, compared to the
general population,39 likely due to the high standard of care
provided in context of the trial. The childhood deaths that
occurred in this study were therefore unlikely to have been repre-
sentative of those that occur in the general pediatric population.
A lack of impact on mortality in phase III trials has also been
observed for other vaccines; no reduction in the number of deaths
was seen in children vaccinated with the oral, live attenuated
human rotavirus vaccine compared to placebo-vaccinated
children.40 However, a significant decline in diarrhea-related
deaths was observed after introduction of rotavirus vaccination
in Mexican children.41
In this context, the apparent increased all-cause mortality in
RTS,S/AS01-vaccinated girls compared to control girls in our
study15 needs to be interpreted with caution. Various causes of
death were reported during the trial, including trauma, malaria,
and other infectious diseases; and no deaths were considered as
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related to vaccination by the investigators or physicians caring for
the children in the study. Mortality in the trial population was
evaluated by modeling known risks factors, but information on
some of these risk factors was not indicated per protocol, and
therefore not systematically collected. Exploratory analyses
revealed that mortality was independently associated with
a number of known risk factors (HIV infection, malnutrition,
anemia, young age). Although none of these factors explained
the apparent excessmortality in female RTS,S/AS01 recipients, the
multiple risk factors for death identified and not accounted for
during randomization underscores the risk of such post-hoc ana-
lyses. The increased risk for mortality in RTS,S/AS01-vaccinated
girls could be the result of the observed low female mortality rate
in the control arm, which at 1.3% was lower than the mortality
rate in all other study arms, bothmale and female.We do not have
data from the trial on gender-specific parental care-seeking
behaviors,42 which might have confounded these gender-specific
mortality outcomes.
Potential limitations of the study include the fact that the self-
controlled case-series for febrile convulsions, gender-specificmor-
tality, and CM cases were analyzed post-hoc and those analyses
were data-driven. These results therefore need to be interpreted
with caution. Furthermore, there was no clinical diagnosis per-
formed for CM as the investigators were not asked to specifically
report CM. Another limitation might be the fact that, in some
cases, children had been treated for malaria before admission to
hospital, which could have influenced the final diagnosis, espe-
cially forCM.Also, the overlap of clinical symptoms formeningitis
and CMand the low proportion of cases for which wewere able to
identify the causative pathogens of meningitis might have led to
over-reporting of cases; this has been evident from the review of
cases by the experts. In addition, the analyses in the different
subpopulations were limited by the low number of participants
in these subpopulations and the fact that the trial was not specifi-
cally designed to assess safety in these subgroups. Finally, while the
sample size of our trial was large, it may not have been sufficient to
detect rare or very rare AEs after RTS,S/AS01 vaccination.
In conclusion, in this trial, RTS,S/AS01 has demonstrated
a positive benefit-risk balance confirming the previous findings.
Febrile convulsions are an identified risk of RTS,S/AS01, similar
to other pediatric vaccines.43 The higher number of meningitis
and cerebral malaria cases in the RTS,S/AS01 groups are not
considered confirmed risks, but rather potential risks given the
low likelihood of these events being caused directly by the
vaccine, the absence of a cluster in time-to-onset after vaccina-
tion, and the low number of cases. These safety signals may be
chance findings but – given their severity – will be further
investigated. The imbalance in mortality between RTS,S/AS01-
vaccinated and control girls could be related to currently
unknown non-specific vaccine effects but should be interpreted
with caution due to the overall low mortality rate in the trial. At
present, the impact of RTS,S/AS01 on mortality is classified as
missing information in the risk management plan.44
Based on the positive benefit-risk balance of RTS,S/AS01
and the potential for substantial impact against clinical and
severe malaria, EMA granted a positive scientific opinion for
this vaccine, and WHO recommended pilot implementation
of the vaccine in children in sub-Saharan Africa.11,12 The
identified safety signals will be closely monitored during this
pilot implementation and in phase IV studies. These studies
will also provide additional real-life data which cannot be
generated in a pre-licensure clinical trial setting.
Figure 4 represents a “focus on the patient” section, which
elaborates on the clinical relevance of the research intended to
be shared with patients by health care professionals.
Patients and methods
Study design and ethics
This phase III, double-blind, randomized, controlled trial
(ClinicalTrials.gov: NCT00866619) was conducted between
March 2009 and January 2014 at 11 centers in 7 SSA coun-
tries: Burkina Faso, Ghana, Gabon, Kenya, Tanzania, Malawi,
and Mozambique. Detailed trial methods have been reported
previously.7–10,45–48 The study was conducted in accordance
with Good Clinical Practice guidelines (Supplementary
methods) and cleared by all institutional review boards of
the countries and centers concerned.
The trial was overseen by an Independent Data Monitoring
Committee (Supplementary methods).
Randomization and blinding
Children 5–17 months and infants 6–12 weeks of age were
randomly assigned (1:1:1 ratio) to receive 4 doses (M0, 1, 2,
20) of RTS,S/AS01 (R3R group) or control vaccine (C3C;
control group), or 3 RTS,S/AS01 doses (M0, 1, 2) plus control
vaccine (M20) (R3C group). Data were collected in an obser-
ver-blind manner; caregivers of participants, and those
responsible for evaluation of study endpoint data were una-
ware which treatment was administered.
Study vaccines
RTS,S/AS01 (GSK, Rixensart, Belgium) contains RTS,S antigen
combined with AS01E Adjuvant System (Supplementary meth-
ods). As control vaccine, infants received meningococcal ser-
ogroup C conjugate vaccine (MenC-CRM, Menjugate, Novartis,
Basel, Switzerland), while older children received 3 doses of rabies
vaccine (Verorab, Sanofi Pasteur, Paris, France), followed by 1
dose of MenC-CRM. Infants received study vaccines concurrently
with routine pediatric vaccines according to each country’s
Expanded Program on Immunization.
Safety assessment per protocol
SAEs were collected throughout the trial by passive surveillance
from M0 to SE for all participants. Solicited symptoms were
collected during a 7-day post-vaccination period and unsolicited
AEs were collected during a 30-day post-vaccination period
among the first 200 participants per age group at each study
site. All hospitalized participants were evaluated for severe
malaria based on predefined markers of severe disease and
a protocol-defined algorithm (Supplementary methods).
Verbal autopsies were conducted on deaths that occurred out-
side study facilities.49 The cause of death was determined by
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a panel of three experienced verbal autopsy reviewers, as
detailed in the Supplementary methods.
The investigators used their clinical judgement to deter-
mine the relationship between the vaccine and the occurrence
of each (S)AE (Supplementary methods).
Individual medical review was performed for all SAEs.
Aggregate safety data were reviewed by a multi-functional
team consisting of all the appropriate disciplines required to
assess any potential safety issue by the trial sponsor. This team
met on a regular basis and when information arose that could
potentially impact the benefit-risk of the vaccine.
Safety (SAEs) was also evaluated in infants and children with
low and very low weight-for-age and in preterm infants
(<37 weeks of gestational age). While there were no protocol-
defined objectives pertaining to the safety analysis of preterm
infants, these data were readily retrievable since the protocol-
defined procedures called for recording gestation in study parti-
cipants in the 6–12 weeks age category. Gestation at birth was
solicited by asking the parent(s)/LAR(s) if their infant was born in
the 37th week of gestation or later. For infants born before the 37th
week, the approximate duration of gestation (in weeks) at birth, as
provided by the parent(s)/LAR(s), was recorded.
AEs of specific interest included convulsions, rashes and
mucocutaneous lesions assessed within 30 days following
vaccination, and pIMDs from M0–SE. The specific interest
in the detailed description of convulsions, rashes and
mucocutaneous lesions resulted from an imbalance in
these AEs observed in a pooled analysis of safety data
from phase II RTS,S trials.26 pIMDs were considered of
specific interest based on the theoretical concern that
administration of an adjuvanted vaccine may interfere
with immunological self-tolerance.
All convulsions occurring within 30 days post-vaccination
were reported as SAEs. Those occurring within 7 days post-
vaccination were recorded and analyzed according to the
BCWG case definition for general convulsive seizures.18 Those
occurring after the 7-day post-vaccination period were diagnosed
and reported by the clinicians as any other SAE.
Rashes and mucocutaneous lesions that occurred within
30 days of vaccination in the first 200 participants enrolled at
each site in the infant age group were reported as AEs/SAEs
and analyzed according to the BCWG case definition.50
Medical documentation of the events was reported in the
electronic case report forms. Rashes and mucocutaneous
lesions that met the criteria for an SAE were reported in all
participants throughout the study period.
pIMDs were recorded as SAEs (M0–SE) according to
a predefined list provided in the protocol (Supplementary
table S4). Additionally, any other AE that could be immune-
mediated in the investigator’s judgment had to be reported
according to the same process. Study investigators were
offered facilitated access to laboratory investigation. The ana-
lysis was performed based on the predefined list of MedDRA
preferred terms and on the investigator’s judgment.
Safety analyses were performed on the intention-to-treat
population, which included all participants who received at
Figure 4. Focus on the patient summary of the findings.
HUMAN VACCINES & IMMUNOTHERAPEUTICS 2395
least 1 vaccine dose. Statistical evaluations of safety endpoints
were descriptive. Proportions of children and infants for
whom (S)AEs were reported were tabulated with exact
95% CIs.
Post-hoc analyses
A self-controlled case series post-hoc analysis was applied on
febrile convulsions within 30 days after any dose in children.
The risk ratio was calculated as the ratio of incidence of events
during a risk period, to the incidence during a control period.
The two risk periods were 3 and 7 days post-vaccination (days
0–2 and 0–6 with day 0 being the day of vaccination), result-
ing in control periods of 27 days (days 3–29) and 23 days
(days 7–29) post-vaccination.
To further assess the safety signal for meningitis iden-
tified in this study, available cerebrospinal fluid samples
from suspected meningitis cases were sent to an external
laboratory to perform PCR analysis (Supplementary
methods). A larger number of SAEs including all CNS
infection/inflammation terms were reviewed by two inde-
pendent external experts, individually and in a blinded
way. The experts independently categorized the cases as:
“confirmed meningitis” if the clinical picture and the
laboratory results were consistent with a diagnosis of
meningitis; “no meningitis” if the clinical picture and
laboratory results were consistent with another diagnosis;
“undetermined” if the clinical picture or laboratory results
were not consistent with a diagnosis of meningitis and not
consistent with another diagnosis, or were missing. The
final categorization of cases required consensus of both
experts (Supplementary methods).
In a post-hoc analysis, hospitalized severe malaria cases
(secondary case definition 1 with parasitemia >5,000/µL;10
Supplementary methods) with BCS ≤2 were identified
from inpatient records by a computer algorithm as
a proxy for CM, regardless of the presence of comorbid-
ities or whether the diagnosis was clinically confirmed by
the investigators. To complement this analysis with clin-
ical expertise, two independent experts in malaria
reviewed all hospitalized severe malaria cases in the 5–
17 months age category with parasitemia >0/µL and with
a BCS of ≤2, or seizure, or prostration to retrospectively
confirm and/or identify any CM case. The experts cate-
gorized the cases as “confirmed CM”, if the case fulfilled
the CM case definition (adapted from the WHO)51: “The
clinical syndrome characterized by coma (unable to localize
a painful stimulus, or BCS <3) maintained for a minimum
of 30 minutes after a convulsion or the correction of hypo-
glycemia, in the presence of asexual P. falciparum parasites
in peripheral blood (>0 parasites/µL), having excluded
other causes of encephalopathy (including meningitis)”;
“uncertain CM” if the case was not sufficiently documen-
ted to either confirm or rule out CM diagnosis; or
“not CM” if the case was more likely due to another
etiology/diagnosis (Supplementary methods).
We performed a post-hoc multivariate Cox regression ana-
lysis to model risk factors known to be associated with
mortality.
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